Study guide

5.2 Cardiovascular and Respiratory Pathophysiology

PEBC Pharmacist Evaluating Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & The Canadian Pharmacy Practice Landscape

1.1 PEBC EE Blueprint, Format, Scoring, and IPG Certification Pathway 1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation 1.3 Canadian Pharmacy Regulatory Framework, NAPRA Standards, and Professional Legislation

2 Chapter 2: Pharmaceutics & Drug Delivery Systems

2.1 Physicochemical Principles, Solubility, Ionization, and Stability 2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies 2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery 2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals 2.5 Pharmaceutical Quality: GMP, Stability Testing, and Bioequivalence

3 Chapter 3: Biopharmaceutics & Clinical Pharmacokinetics

3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME) 3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS) 3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations 3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application

4 Chapter 4: Pharmacology, Toxicology & Pharmacogenetics

4.1 Autonomic and Central Nervous System Pharmacology 4.2 Cardiovascular, Renal, and Endocrine Pharmacology 4.3 Clinical Toxicology, Overdose Management, and Antidotes 4.4 Biologics, Biosimilars, and Pharmacogenetics

5 Chapter 5: Pathophysiology & Clinical Assessment

5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs 5.2 Cardiovascular and Respiratory Pathophysiology 5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology 5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology 5.5 Physical Assessment and Point-of-Care Testing

6 Chapter 6: Pharmacotherapy & Minor Ailments

6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines 6.2 Endocrine and Metabolic Pharmacotherapy 6.3 Infectious Diseases and Antimicrobial Stewardship 6.4 Neurologic, Psychiatric, and Pain Management Therapeutics 6.5 Minor Ailment Prescribing and Nonprescription Therapy 6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy 6.7 Gastrointestinal and Hepatic Pharmacotherapy 6.8 Renal, Fluid, and Electrolyte Therapeutics 6.9 Musculoskeletal and Rheumatologic Pharmacotherapy 6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy 6.11 Hematologic, Immunologic, and Oncology Supportive Care 6.12 Women's Health, Men's Health, and Urologic Therapeutics 6.13 Nutrition, Natural Health Products, and Complementary Medicine

7 Chapter 7: Special Populations & Applied Therapeutics

7.1 Geriatric Pharmacotherapy and Deprescribing 7.2 Pediatric and Neonatal Pharmacotherapy 7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation 7.4 Dosage Adjustments in Renal and Hepatic Impairment

8 Chapter 8: Prescription Processing, Calculations & Compounding

8.1 Prescription Processing, Verification, and Drug Therapy Problem Management 8.2 Pharmaceutical Calculations and Clinical Math 8.3 Non-Sterile Compounding and NAPRA Standards 8.4 Sterile and Hazardous Compounding under NAPRA Standards 8.5 Advanced Calculations: Infusion Rates, Parenteral Nutrition, and Renal Estimation

9 Chapter 9: Health Equity, Indigenous Health & Pharmacy Bioethics

9.1 Social Determinants of Health and Health Equity 9.2 Indigenous Health, Cultural Safety, and Humility 9.3 Pharmacy Bioethics, Informed Consent, and Professional Boundaries 9.4 Health Promotion, Disease Prevention, and Public Health

10 Chapter 10: Evidence Appraisal, Safety & Practice Management

10.1 Biostatistics and Critical Appraisal of Clinical Literature 10.2 Pharmacoeconomics and Pharmacoepidemiology 10.3 Medication Safety, Incident Analysis, and Quality Improvement 10.4 Pharmacy Operations, Cold-Chain Management, and Emergency Preparedness 10.5 Drug Information and Evidence-Based Decision Making 10.6 Pharmacovigilance and Adverse Drug Reaction Reporting in Canada

11 Chapter 11: Patient Care Process, Communication & Collaborative Practice

11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up 11.2 Patient and Caregiver Communication, Education, and Health Literacy 11.3 Motivational Interviewing and Shared Decision-Making 11.4 Intra- and Interprofessional Collaborative Care

12 Chapter 12: Medication Administration, Devices & Expanded Scope

12.1 Injection and Vaccine Administration Technique 12.2 Immunization Schedules, Vaccine Selection, and Travel Health 12.3 Home Medical Devices and Device Technique Coaching 12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation

13 Chapter 13: Pharmacy Management, Finance & Practice Leadership

13.1 Human Resources, Leadership, and Change Management 13.2 Financial Management, Drug Plans, and Marketing 13.3 Quality Improvement, Risk Management, and Workplace Safety

5.2 Cardiovascular and Respiratory Pathophysiology

Key Takeaways Explain This Topic AI

Atherosclerosis progresses from endothelial dysfunction and oxidized LDL uptake by macrophages to fibrous plaque formation, which upon rupture triggers acute coronary thrombus formation.

Heart failure with reduced ejection fraction (HFrEF; LVEF <= 40%) involves eccentric remodeling and systolic contractile failure, whereas heart failure with preserved ejection fraction (HFpEF; LVEF >= 50%) is characterized by concentric hypertrophy and impaired diastolic ventricular filling.

Atrial fibrillation causes loss of coordinated atrial contraction ('atrial kick') and blood stasis in the left atrial appendage, substantially elevating thromboembolic stroke risk.

Asthma is characterized by T2-high eosinophilic airway inflammation with significant reversible airflow limitation, whereas COPD is characterized by neutrophilic inflammation, alveolar destruction (emphysema), mucus hypersecretion, and fixed post-bronchodilator airflow obstruction (FEV1/FVC < 0.70).

Last updated: August 2026

5.2 Cardiovascular and Respiratory Pathophysiology

Exam Focus: Evaluating cardiovascular and respiratory pathophysiology requires understanding vascular remodeling, neurohormonal feedback loops, electrophysiological aberrancies, and pulmonary airflow mechanics. Candidates must master the pathophysiological differences between systolic and diastolic heart failure, ischemic coronary syndromes, cardiac arrhythmias (such as atrial fibrillation and QT prolongation), and obstructive airway diseases (asthma versus COPD) according to Canadian clinical practice standards.

  • Cardiovascular Pathophysiology
  • 1. Hypertension: Vascular Remodeling and Pathogenesis

Systemic arterial blood pressure is the mathematical product of Cardiac Output (CO) and Total Peripheral Resistance (TPR): Mean Arterial Pressure (MAP) = Cardiac Output (CO) × Systemic Vascular Resistance (SVR) \text{Mean Arterial Pressure (MAP)} = \text{Cardiac Output (CO)} \times \text{Systemic Vascular Resistance (SVR)} Mean Arterial Pressure (MAP) = Cardiac Output (CO) × Systemic Vascular Resistance (SVR)

Primary (Essential) Hypertension ( > 90 % > 90\% > 90% of cases): Multi-factorial etiology driven by:

Sympathetic Nervous System (SNS) Overactivity: Increased circulating catecholamines elevate heart rate, inotropic contractility, and peripheral arteriolar vasoconstriction.

Renin-Angiotensin-Aldosterone System (RAAS) Activation: Excessive angiotensin II production promotes potent direct vasoconstriction, vascular smooth muscle hypertrophy, oxidative stress, and aldosterone-mediated renal sodium and water retention.

Vascular Endothelial Dysfunction: Reduced bioavailability of the vasodilator nitric oxide (NO) coupled with increased endothelin-1 yields basal vasoconstriction and progressive arterial wall stiffening.

Renal Sodium Excretion Defect: A rightward shift in the pressure-natriuresis curve impairs renal sodium excretion at normal arterial pressures.

Secondary Hypertension ( < 10 % < 10\% < 10% of cases): Identified by identifiable underlying causes: Renal Artery Stenosis (atherosclerotic or fibromuscular dysplasia), Chronic Kidney Disease, Primary Aldosteronism (Conn's syndrome; unprovoked hypokalemia with suppressed plasma renin), Pheochromocytoma (catecholamine-secreting chromaffin tumor), Cushing's syndrome, Obstructive Sleep Apnea (OSA), and drug-induced etiologies ( NSAIDs , systemic decongestants [pseudoephedrine], oral contraceptives, systemic corticosteroids, calcineurin inhibitors [tacrolimus, cyclosporine], and VEGF inhibitors [bevacizumab]).

Hypertensive Crises ( BP > 180 / 120 mmHg \text{BP} > 180/120\text{ mmHg} BP > 180/120 mmHg ):

Hypertensive Urgency: Severe blood pressure elevation without acute target-organ damage. Managed with oral antihypertensive agents over 24 to 48 hours.

Hypertensive Emergency: Severe blood pressure elevation with acute, life-threatening target-organ injury (hypertensive encephalopathy, acute aortic dissection, acute myocardial infarction, acute pulmonary edema, or acute renal failure). Mandates immediate admission to an intensive care setting for titrated intravenous antihypertensive therapy (e.g., labetalol, nicardipine, sodium nitroprusside), aiming for a controlled blood pressure reduction of no more than 20 % to 25 % 20\%\text{ to }25\% 20% to 25% within the first hour to prevent cerebral and coronary hypoperfusion. +-------------------------------------------------------------------------+

  • | PATHOGENESIS OF ATHEROSCLEROSIS |
  • +-------------------------------------------------------------------------+
  • | |
  • | 1. Endothelial Injury (Hypertension, Smoking, Hyperlipidemia, Toxins) |
  • | | |
  • | v |
  • | 2. Subendothelial Infiltration & Oxidation of LDL Particles |
  • | | |
  • | v |
  • | 3. Monocyte Adhesion, Transmigration, & Differentiation to Macrophages |
  • | | |
  • | v |
  • | 4. Scavenger Receptor Uptake of Ox-LDL -> Foam Cell Formation |
  • | | |
  • | v |
  • | 5. Fatty Streak Formation & VSMC Proliferation (Fibrous Cap Deposition)|
  • | | |
  • | v |
  • | 6. Plaque Rupture / Erosion -> Platelet Thrombus -> Occlusive ACS |
  • | |
  • +-------------------------------------------------------------------------+
  • 2. Atherosclerosis and Ischemic Heart Disease (CAD)

Atherogenesis represents a chronic, lipid-driven inflammatory process affecting large and medium-sized muscular arteries:

Endothelial Dysfunction: Hemodynamic shear stress, cigarette toxins, elevated LDL, and hyperglycemia disrupt endothelial integrity, upregulating vascular cell adhesion molecules (VCAM-1).

Lipid Accumulation and Oxidation: Circulating LDL particles penetrate the subendothelial space of the intima, where they undergo enzymatic and non-enzymatic oxidation (ox-LDL).

Foam Cell and Fatty Streak Generation: Circulating monocytes adhere to VCAM-1, migrate into the intima, differentiate into tissue macrophages, and internalize ox-LDL via scavenger receptors (SR-A, CD36). The resulting lipid-laden foam cells aggregate to form macroscopic fatty streaks .

Fibrous Cap Formation: Secretion of PDGF and TGF- β \beta β stimulates vascular smooth muscle cells (VSMCs) to migrate from the media into the intima, synthesizing extracellular collagen matrix to form a protective fibrous cap over the necrotic lipid core.

Plaque Vulnerability and Rupture: Macrophages within unstable plaques secrete matrix metalloproteinases (MMPs) that degrade collagen in the fibrous cap. Cap thinning and hemodynamic stress precipitate rupture, exposing the thrombogenic lipid core and tissue factor to flowing blood, triggering immediate platelet adhesion, activation, and occlusive thrombus formation.

The Clinical Spectrum of Ischemic Heart Disease

Clinical Entity Pathophysiological Mechanism Biomarkers (Troponin) ECG Findings

Stable Angina Fixed atherosclerotic plaque ( > 70 % > 70\% > 70% stenosis); transient myocardial ischemia during physical/emotional exertion; demand exceeds supply Negative Transient ST-segment depression during episodes; normal at rest

Unstable Angina (UA) Non-occlusive, mural thrombus over ruptured plaque; ischemia at rest or with accelerating pattern Negative ST-segment depression or T-wave inversion; no ST-elevation

NSTEMI Partially occlusive thrombus causing subendocardial myocardial necrosis Positive (elevated hs-cTn) ST-segment depression, prominent T-wave inversion, or normal

STEMI Complete, persistent coronary artery occlusion causing transmural myocardial necrosis Positive (elevated hs-cTn) Persistent ST-segment elevation ≥ 1 mm \ge 1\text{ mm} ≥ 1 mm in ≥ 2 \ge 2 ≥ 2 contiguous leads (or new LBBB) followed by pathological Q waves

3. Heart Failure: Systolic vs Diastolic Dysfunction and Remodeling

Heart failure is a complex clinical syndrome resulting from structural or functional cardiac impairment that reduces the ability of the ventricles to fill or eject blood. +-------------------------------------------------------------------------+

  • | HEART FAILURE: PHENOTYPIC DIFFERENTIATION |
  • +-------------------------------------------------------------------------+
  • | |
  • | [HFrEF] (LVEF <= 40%) [HFpEF] (LVEF >= 50%) |
  • | - Systolic Contractile Failure - Diastolic Filling Impairment |
  • | - Eccentric Hypertrophy - Concentric Hypertrophy |
  • | - Dilated, Thin-Walled LV - Stiff, Thickened LV Wall |
  • | - Increased End-Diastolic Volume - Elevated Filling Pressures |
  • | - Common: Ischemia, Dilated CM - Common: Aging, HTN, Obesity |
  • | |
  • +-------------------------------------------------------------------------+

Heart Failure with Reduced Ejection Fraction (HFrEF; LVEF ≤ 40 % \text{LVEF} \le 40\% LVEF ≤ 40% ):

Primary defect: Impaired myocardial contractility (systolic failure) and progressive ventricular dilatation ( eccentric hypertrophy ).

Etiologies: Myocardial infarction, coronary artery disease, chronic volume overload, dilated cardiomyopathy.

Ventricular wall stress leads to progressive cardiomyocyte apoptosis, interstitial fibrosis, and spherical geometric remodeling.

Heart Failure with Preserved Ejection Fraction (HFpEF; LVEF ≥ 50 % \text{LVEF} \ge 50\% LVEF ≥ 50% ):

Primary defect: Impaired ventricular relaxation and increased myocardial stiffness during diastole (diastolic failure), resulting in elevated left ventricular end-diastolic filling pressures despite a preserved ejection fraction.

Pathogenesis: Systemic microvascular endothelial inflammation driven by comorbidities (hypertension, diabetes, obesity, advanced age, CKD), causing cardiomyocyte concentric hypertrophy and myocardial collagen deposition.

Neurohormonal Maladaptation in Heart Failure:

Sympathetic Activation: Low cardiac output stimulates baroreceptors, triggering sustained norepinephrine release. This causes peripheral vasoconstriction, elevated afterload, tachycardia, and down-regulation of β 1 \beta_1 β 1 ​ -adrenergic receptors, directly promoting myocardial fibrosis and arrhythmogenesis.

RAAS Activation: Renal hypoperfusion triggers renin secretion. Angiotensin II induces systemic vasoconstriction, oxidative damage, and ventricular remodeling, while aldosterone stimulates myocardial interstitial collagen deposition and renal sodium/water retention.

Natriuretic Peptide System: Ventricular stretch stimulates release of ANP and BNP/NT-proBNP, promoting natriuresis, diuresis, and vasodilation. Endogenous neutral endopeptidase ( neprilysin ) degrades these beneficial natriuretic peptides. Inhibiting neprilysin (via sacubitril) augments endogenous peptide signaling.

4. Cardiac Electrophysiology, Arrhythmias, and Conduction Abnormalities

Atrial Fibrillation (AF): Rapid, chaotic atrial depolarization ( 350 to 600 bpm 350\text{ to }600\text{ bpm} 350 to 600 bpm ) originating predominantly within sleeves of atrial myocardium extending into the pulmonary veins . Loss of organized atrial contraction ("atrial kick") reduces cardiac output by 20 % to 30 % 20\%\text{ to }30\% 20% to 30% . Sluggish, turbulent blood flow within the left atrial appendage (LAA) causes local stasis, promoting intra-atrial thrombus formation and systemic thromboembolic stroke. Diagnosed on ECG by absent discrete P waves, fibrillatory baseline waves, and an irregularly irregular ventricular rhythm.

Ventricular Tachyarrhythmias:

Ventricular Tachycardia (VT): Three or more consecutive broad QRS complexes ( > 120 ms > 120\text{ ms} > 120 ms ) originating below the bundle of His at a rate > 100 bpm > 100\text{ bpm} > 100 bpm . Driven by myocardial scar reentry post-infarction or automaticity.

Ventricular Fibrillation (VF): Disorganized, chaotic ventricular depolarization without mechanical cardiac output, causing sudden cardiac death.

Acquired Long QT Syndrome and Torsades de Pointes (TdP):

Delayed myocardial repolarization caused by block of the rapid delayed rectifier potassium current ( I K r I_{Kr} I Kr ​ , encoded by hERG gene). Prolongation of the corrected QT interval ( QTc > 450 ms \text{QTc} > 450\text{ ms} QTc > 450 ms in men, > 460 ms > 460\text{ ms} > 460 ms in women; QTc > 500 ms \text{QTc} > 500\text{ ms} QTc > 500 ms represents a critical risk threshold) allows early afterdepolarizations (EADs) during phase 2 or 3 of the action potential to trigger Torsades de Pointes , a polymorphic ventricular tachycardia exhibiting a characteristic "twisting of the points" around the isoelectric line.

High-risk drug classes include antiarrhythmics (Class IA: procainamide, quinidine; Class III: amiodarone, sotalol), macrolide and fluoroquinolone antibiotics, azole antifungals, typical/atypical antipsychotics (haloperidol, ziprasidone), tricyclic antidepressants, methadone, and citalopram/escitalopram.

5. Venous Thromboembolism (VTE)

Venous thromboembolism encompasses Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), governed by Virchow's Triad :

Endothelial Injury: Vessel wall trauma, surgery (total hip/knee arthroplasty), central venous catheterization.

Venous Stasis: Immobilization, prolonged hospitalization, travel, obesity, heart failure.

Hypercoagulability: Active malignancy, pregnancy, exogenous estrogens (OCPs/HRT), antiphospholipid syndrome, genetic thrombophilias (Factor V Leiden mutation, Prothrombin G20210A, Antithrombin III deficiency, Protein C/S deficiency).

Pulmonary Embolism Pathophysiology: Detachment of an embolus from proximal lower-extremity deep veins travels through the inferior vena cava and right heart chambers to lodge in pulmonary arterial branches. This causes immediate ventilation-perfusion ( V / Q V/Q V / Q ) mismatch , acute increase in pulmonary vascular resistance, right ventricular strain/dilation, acute tricuspid regurgitation, systemic hypotension, and cardiogenic shock.

  • Respiratory Pathophysiology +-------------------------------------------------------------------------+
  • | ASTHMA VS COPD PATHOPHYSIOLOGY |
  • +-------------------------------------------------------------------------+
  • | |
  • | [ASTHMA] [COPD] |
  • | - Etiology: Allergens, Genetics - Etiology: Tobacco, Toxins |
  • | - Inflammation: Eosinophils, CD4+ T - Inflammation: Neutrophils, CD8|
  • | - Cytokines: IL-4, IL-5, IL-13, IgE - Cytokines: LTB4, TNF-a, IL-8 |
  • | - Pathology: Airway hyperreactive, - Pathology: Emphysema, mucus |
  • | smooth muscle hypertrophy gland hypertrophy, air trap |
  • | - Airflow Obstruction: REVERSIBLE - Airflow Obstruction: FIXED |
  • | |
  • +-------------------------------------------------------------------------+
  • 1. Asthma: Immunopathogenesis and Airway Remodeling

Asthma is a heterogeneous chronic inflammatory disease of the conducting airways characterized by recurring episodes of wheezing, breathlessness, chest tightness, and cough with variable expiratory airflow limitation.

Type 2 (T2-High) Eosinophilic Allergic Pathway:

Inhaled allergens are captured by dendritic cells and presented to naive T helper cells, driving differentiation into T H 2 T_H2 T H ​ 2 cells .

T H 2 T_H2 T H ​ 2 cells secrete specific interleukins:

IL-4 & IL-13: Stimulate B-cell immunoglobulin class switching to IgE . IgE binds to high-affinity F c ϵ R I Fc\epsilon RI F cϵ R I receptors on mast cells.

IL-5: Mediates eosinophil differentiation, maturation, bone marrow release, and survival.

IL-13: Promotes goblet cell hyperplasia, mucus hypersecretion, and direct bronchial hyperresponsiveness.

Early-Phase Reaction (minutes): Allergen cross-links IgE on mast cells, triggering degranulation and release of preformed histamine, leukotrienes ( L T C 4 , L T D 4 , L T E 4 LTC_4, LTD_4, LTE_4 L T C 4 ​ , L T D 4 ​ , L T E 4 ​ ), and prostaglandin P G D 2 PGD_2 PG D 2 ​ , causing acute bronchospasm and microvascular leakage.

Late-Phase Reaction (4 to 8 hours): Infiltration of recruited eosinophils, basophils, and neutrophils releasing major basic protein, eosinophil cationic protein, and reactive oxygen species, sustaining chronic mucosal inflammation.

Airway Remodeling: Repeated cycles of inflammation and repair lead to permanent structural modifications: subepithelial basement membrane thickening (collagen deposition), bronchial smooth muscle hypertrophy and hyperplasia, goblet cell metaplasia, and subepithelial neovascularization, causing progressive non-reversible airflow decline over time.

2. Chronic Obstructive Pulmonary Disease (COPD)

COPD is characterized by persistent, usually progressive airflow limitation associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases (predominantly cigarette smoke and biomass fuels).

Non-Type 2 Neutrophilic and Macrophagic Inflammation: Inhaled oxidants activate alveolar macrophages and epithelial cells to release chemotactic factors ( IL-8 , Leukotriene B 4 B_4 B 4 ​ [ L T B 4 LTB_4 L T B 4 ​ ]), recruiting neutrophils and C D 8 + CD8^+ C D 8 + cytotoxic T lymphocytes . Neutrophils release proteolytic enzymes, including neutrophil elastase , matrix metalloproteinases (MMPs), and cathepsins.

Pathological Components:

Chronic Bronchitis: Small airway disease (obstructive bronchiolitis). Chronic irritants cause goblet cell hyperplasia and hypertrophy of submucosal mucus glands (elevated Reid Index > 0.50 > 0.50 > 0.50 ), excessive mucus secretion, ciliary dysfunction, and luminal mucus plugging. Clinically defined as a productive cough on most days for at least 3 consecutive months in 2 successive years.

Emphysema: Protease-antiprotease imbalance. Excessive neutrophil elastase overwhelms endogenous antiproteases (such as α 1 \alpha_1 α 1 ​ -antitrypsin ). This causes enzymatic destruction of alveolar elastin and alveolar septal walls, producing irreversible enlargement of air spaces distal to terminal bronchioles.

Dynamic Hyperinflation and Air Trapping: Destruction of alveolar attachments reduces elastic tethering of small airways, causing premature expiratory airway collapse. Air becomes trapped in the lungs during expiration, progressively elevating end-expiratory lung volume (dynamic hyperinflation), flattening the diaphragm, impairing mechanical inspiratory efficiency, and generating the clinical "barrel chest" deformity.

3. Spirometric Diagnostics: Obstructive vs Restrictive Defects

Spirometric Parameter Normal Baseline Obstructive Defect (Asthma / COPD) Restrictive Defect (Pulmonary Fibrosis)

FEV 1 / FVC \text{FEV}_1 / \text{FVC} FEV 1 ​ / FVC Ratio ≥ 0.70 to 0.80 \ge 0.70\text{ to }0.80 ≥ 0.70 to 0.80 Reduced ( < 0.70 < 0.70 < 0.70 ) Normal or Elevated ( > 0.70 > 0.70 > 0.70 )

Forced Expiratory Volume in 1 sec ( FEV 1 \text{FEV}_1 FEV 1 ​ ) ≥ 80 % \ge 80\% ≥ 80% predicted Reduced Reduced

Forced Vital Capacity ( FVC \text{FVC} FVC ) ≥ 80 % \ge 80\% ≥ 80% predicted Normal or mildly reduced Markedly Reduced ( < 80 % < 80\% < 80% predicted)

Total Lung Capacity (TLC) 80 % to 120 % 80\%\text{ to }120\% 80% to 120% Elevated (air trapping) Reduced ( < 80 % < 80\% < 80% predicted)

Bronchodilator Reversibility N/A Asthma: Significant improvement ( Δ FEV 1 ≥ 12 % \Delta \text{FEV}_1 \ge 12\% Δ FEV 1 ​ ≥ 12% AND ≥ 200 mL \ge 200\text{ mL} ≥ 200 mL ); COPD: Incomplete reversibility (persistent post-BD FEV 1 / FVC < 0.70 \text{FEV}_1/\text{FVC} < 0.70 FEV 1 ​ / FVC < 0.70 ) Minimal or no bronchodilator response

4. Lower Respiratory Infections and Gas Exchange Failure

Pneumonia: Inhalation or aspiration of pathogens (e.g., Streptococcus pneumoniae ) overwhelms alveolar macrophage defenses. Infection triggers an acute inflammatory cascade characterized by intra-alveolar exudation of protein-rich fluid, neutrophils, and erythrocytes ( consolidation ).

Pathophysiology of Hypoxemia: Consolidated, non-ventilated alveoli continue to receive pulmonary capillary blood flow, creating severe intrapulmonary right-to-left shunting (areas where ventilation V = 0 V = 0 V = 0 with perfusion Q > 0 Q > 0 Q > 0 ). This extreme form of ventilation-perfusion ( V / Q V/Q V / Q ) mismatch impairs alveolar-capillary oxygen diffusion, leading to hypoxemic respiratory failure.